| 20.18 -0.56 (-2.7%) | 04-25 10:14 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 24.91 | 1-year : | 25.96 |
| Resists | First : | 21.33 | Second : | 22.22 |
| Pivot price | 20.79  |
|||
| Supports | First : | 19.87 | Second : | 16.54 |
| MAs | MA(5) : | 20.57  |
MA(20) : | 20.95 |
| MA(100) : | 24.75 |
MA(250) : | 29.45 |
|
| MACD | MACD : | -0.6 |
Signal : | -0.7 |
| %K %D | K(14,3) : | 38.6 |
D(3) : | 36.2 |
| RSI | RSI(14): 39.1 |
|||
| 52-week | High : | 44.09 | Low : | 19.87 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ FLGT ] has closed above bottom band by 38.6%. Bollinger Bands are 38.7% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 20.78 - 20.84 | 20.84 - 20.91 |
| Low: | 20.23 - 20.31 | 20.31 - 20.39 |
| Close: | 20.61 - 20.72 | 20.72 - 20.85 |
Fulgent Genetics, Inc., together with its subsidiaries, provides COVID-19, molecular diagnostic, and genetic testing services to physicians and patients in the United States and internationally. The company offers genetic tests comprising Focus and Comprehensive oncology panels tests; Beacon carrier screening panels test for inherited conditions; solid tumor molecular profiling for somatic cancer testing; rapid whole genome testing for children in NICU and PICU; newborn genetic analysis panel; single front-line test to detect ataxia-related variants and repeat expansions through sequencing; picture genetics, a patient-initiated genetic testing; whole exome and clinical exome panel tests; whole genome, mutation, and repeat expansion testing services, as well as research service tests. It also provides next generation sequencing and reverse transcription polymerase chain reaction-based tests, as well as antigen-based diagnostic tests for the detection of SARS-CoV-2. In addition, the company offers flow cytometry, a cell analysis technique providing diagnosis, prognosis, and monitoring of malignancies; fluorescence in-situ hybridization for detecting and locating a specific DNA sequence on a chromosome; immunohistochemistry, an imaging technique used to visualize antigens in cells; cytogenetics, which analyzes the chromosome set for numerical and structural abnormalities; and molecular testing that includes hematopoietic and solid tumor molecular assays. The company serves insurance, hospitals, medical institutions, other laboratories, governmental bodies, payors, municipalities and large corporations, and patients. Fulgent Genetics has strategic partnership with Helio Health, Inc. to commercialize blood-based early cancer detection tests. The company was formerly known as Fulgent Diagnostics, Inc. and changed its name to Fulgent Genetics, Inc. in August 2016. Fulgent Genetics, Inc. was founded in 2011 and is headquartered in Temple City, California.
Tue, 23 Apr 2024
Mirae Asset Global Investments Co. Ltd. Has $1.27 Million Position in Fulgent Genetics, Inc. (NASDAQ:FLGT) - MarketBeat
Thu, 11 Apr 2024
Fulgent Genetics to Announce First Quarter 2024 Financial Results on Friday, May 3, 2024 - Business Wire
Fri, 01 Mar 2024
An Intrinsic Calculation For Fulgent Genetics, Inc. (NASDAQ:FLGT) Suggests It's 32% Undervalued - Yahoo Finance
Wed, 28 Feb 2024
Fulgent Genetics Shares Business Insights in Investor Update - TipRanks.com - TipRanks
Wed, 28 Feb 2024
Fulgent Genetics (FLGT) Q4 2023 Earnings Call Transcript - Seeking Alpha
Wed, 28 Feb 2024
Fulgent Genetics Inc (FLGT) Faces GAAP Loss Despite Core Revenue Growth in 2023 - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Diagnostics & Research
|
|
| Shares Out | 30 (M) |
| Shares Float | 20 (M) |
| Held by Insiders | 32.5 (%) |
| Held by Institutions | 49 (%) |
| Shares Short | 604 (K) |
| Shares Short P.Month | 498 (K) |
| EPS | -5.64 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 38.31 |
| Profit Margin | -58.1 % |
| Operating Margin | -47.5 % |
| Return on Assets (ttm) | -3.5 % |
| Return on Equity (ttm) | -14.6 % |
| Qtrly Rev. Growth | 4 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 9.67 |
| EBITDA (p.s.) | -1.56 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 27 (M) |
| Levered Free Cash Flow | 26 (M) |
| PE Ratio | -3.66 |
| PEG Ratio | 0.3 |
| Price to Book value | 0.53 |
| Price to Sales | 2.12 |
| Price to Cash Flow | 22.8 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|